Momelotinib

Overview

Momelotinib is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL1078178).

Patent & exclusivity (US)

Per the FDA Orange Book (3 approved US products), the latest listed US patent on Momelotinib expires 2 Dec 2040 and exclusivity 15 Sept 2030. Generic API sourcing typically opens up once these lapse.

Chemical identity

IUPAC name

N-(cyanomethyl)-4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]benzamide

Canonical SMILES

C1COCCN1C2=CC=C(C=C2)NC3=NC=CC(=N3)C4=CC=C(C=C4)C(=O)NCC#N

InChIKey

ZVHNDZWQTBEVRY-UHFFFAOYSA-N